FDA Commissioner Scott Gottlieb, MD, indicated that the agency would be putting forward policies that would compel branded drug makers to “tighten up their manufacturing, to have less variance of their biologics that are currently on the market.” In theory, this change could make it easier to develop a biosimilar using smaller studies.
In an interview today with CNBC’s Meg Tirrell at the Healthy Returns conference, FDA Commissioner Scott Gottlieb, MD said that early estimates of savings that could be garnered through biosimilars in the United States “probably weren’t realistic.” That said, “I think we will see a lot of biosimilar competition come on to the market. And I also think we're going to see more consumer and provider acceptance of using biosimilars.”
Gottlieb explained that the FDA is working on “advancing new policies to try to stimulate more biosimilar development. We're taking a hard look at how we determine interchangeability so that we can make determinations that biosimilars can be used interchangeably with the brand of drugs.”
Notably, Gottlieb said that, in looking at currently marketed biologics, “We see a lot of variants in lot-to-lot manufacturing of existing biologics and also a lot of variance in the products over time where there's drift in the sort of formulation of the biologics that are currently on the market. And those don't seem to have clinical consequence. But they could have clinical consequence.”
Product drift also makes biosimilar development more challenging, because “you have sort of a moving target on the market and you want to come in and create a biosimilar to copy it, you have to study your biosimilar against more drugs, more patients, because there's more variability in the currently marketed brand of drugs.”
Gottlieb indicated that the agency would be putting forward policies that would compel branded drug makers to “tighten up their manufacturing, to have less variance of their biologics that are currently on the market.” In theory, this change could make it easier to develop a biosimilar using smaller studies, he said.
When asked whether these policies will stimulate greater development of biosimilars, Gottlieb said that biosimilars would be “slow build,” but that the FDA is working on about “a dozen policies” concerning biosimilars. Yet there remain impediments to biosimilars, “whether it's distributive PBM or the health plan with these kickbacks, these rebates.” Providers, he said, will have to decide whether they will help to create a robust market, “Because if we don't see soon the ability of the biosimilars when they come to market to actually build market share, I'm worried that when manufacturers look at this market, they're going to say: ‘Look, this is too hard.’ We can't get more than 10 percent market share, so we're not going to make the investment.”
These comments come just weeks after Gottlieb addressed America’s Health Insurance Plans at its National Health Policy Conference, saying that “The economics of development are currently unstable; and the pipeline of biosimilar products that we hope for could be dramatically affected by the weakening of market incentives to bring these products to patients.”
Biosimilar Policy Roundup—September 2024
October 1st 2024In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the industry and highlighting broader trends in market dynamics and regulatory challenges.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.